Upcoming FDA+Cannabinoids meeting could shake things up for hemp and cannabis stocks... "June 14, 2022 Meeting of the Science Board to the FDA"... Agenda: The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. The Science Board to the Food and Drug Administration will consider challenges in evaluating the safety of dietary supplement and food ingredients with predicted pharmacological activity, utilizing cannabinoids as a case study. https://www.federalregister.gov/documents/2022/05/18/2022-10697/science-board-to-the-food-and-drug-administration-advisory-committee-notice-of-meeting https://www.fda.gov/advisory-committees/science-board-food-and-drug-administration/2022-meeting-materials-science-board-fda Other ingredients used in supplements and food available in the US also could be on the agency's radar for generating pharmacological activity. Those ingredients include: kratom, a botanical marketed for its calming and anti-inflammatory benefits; the amino acid N-acetyl-L-cysteine used to increase glutathione levels and support respiratory health and detoxification in the liver and kidney; and numerous analogs of pharmaceutical stimulants used in non-compliant weight loss and sports training supplements. Cannabinoids, though, are the focus of this Science Board discussion. And for good reason. https://hbw.pharmaintelligence.informa.com/RS152545/Everywhere-In-Supplements-And-Food-Is-Hemp-Safe-Enough-To-Be-Lawful-US-FDA-Wants-Science-Boards-Help-Solving-Regulatory-Conundrum